ADI-PEG 20: Phase I started

Polaris began an open-label, dose-escalation, U.S. Phase I trial to evaluate once-weekly 4.5, 9 and 18 mg/m 2 intramuscular ADI-PEG 20 in about 30 pediatric patients who have failed prior treatment an...